Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21325539 | 0.84 | GRN (0.32) | GRNSORT1 | |
| SCHEMBL17760504 | 0.78 | KDM4E (0.36) | — | |
| SCHEMBL17721217 | 0.78 | ALDH1A1 (0.37) | — | |
| SCHEMBL1767744 | 0.77 | AAK1 (0.31) | — | |
| SCHEMBL1370741 | 0.76 | — | — | |
| SCHEMBL18501678 | 0.75 | — | — | |
| SCHEMBL25025259 | 0.73 | CYP2C19 (0.38) | NPC1MEN1KMT2A | |
| SCHEMBL7982137 | 0.73 | — | — | |
| SCHEMBL17709787 | 0.72 | ABCB11 (0.38) | — | |
| SCHEMBL16033555 | 0.72 | KDM4E (0.42) | NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544108-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2020-01-28 | — | — | US | disclosed |
| US-8822485-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130018064-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2504330-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063272-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544108-B2 | Hydrazide containing nuclear transport modulators and uses thereof | XPO1, KPNA1, ABCB11 | GRN 2845/4885SORT1 3811/4885NPC1 42/4885 |
| US-20130018064-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | GRN 1899/4885SORT1 2397/4885NPC1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.